Skip to main content
Premium Trial:

Request an Annual Quote

Burnham to Study Drug Targets for J&J

NEW YORK (GenomeWeb News) — The Burnham Institute for Medical Research has inked an assay-development and license agreement with Johnson & Johnson Pharmaceutical Research and Development that will give the drug maker access to some of Burnham's high-throughput screening technologies to study drug targets for inflammatory diseases, Burnham said on Monday.

Burnham CEO John Reed said in a statement that he thinks the collaboration, which is the institute's first with a large pharma, "will foster the discovery of drug products with real clinical potential."

Financial terms of the multi-year agreement were not released.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.